Apollo Hospitals: Simplifying corporate structure could lead to rerating
Apollo Healthco will have online, offline, retail, and wholesale pharmacy segments under one umbrella, apart from the digital consultation and treatment business of Apollo 24|7.
The new entity will have nearly 667 million equity shares with a face value of ₹2 each.
Apollo Hospitals' shareholders will receive 195.2 shares of Apollo Healthco for every 100 shares they hold. Apollo Healthco's listing is likely in 18-21 months. The exercise would mean that Apollo Hospitals would only have a 17.5% stake (direct plus indirect through its other subsidiaries) in Apollo Healthco, as against the earlier plan of having a 59.2% stake.
Also Read: Will Torrent Pharma's big bet on JB Chemicals pay off?
The two separate listed entities with dedicated leadership will allow the management teams to sharpen their focus on hospital and pharmacy businesses separately.
Following the announcement, Apollo Hospitals shares touched a new 52-week high of ₹7,584.50 apiece on Tuesday.
Growth potential
Is there more steam left based on the separate valuation of the two businesses? Well, the answer depends on the management's ability to achieve the aspirational targets for its pharmacy business—Apollo Healthco.
According to the company's presentation, Apollo Healthco's FY25 revenue (pro forma without the restructuring) was ₹16,377 crore. The management aspires for an operating revenue of ₹25,000 crore in FY27, which would mean a compound annual growth rate of 24% over the two years from FY25. This would require a significant pick-up in growth, given that the FY25 revenue had increased 19% year-on-year.
Excluding Apollo 24|7 losses, the FY25 Ebitda margin was already about 6%. So, the Ebitda margin target of 7% in FY27 with operational efficiencies is achievable as it would only require Apollo 24|7 to achieve breakeven.
If management is able to deliver on the aspirational numbers, it would mean an Ebitda of ₹1,750 crore in FY27. Based on the EV/ Ebitda multiple of 30x assigned by analysts at Nomura, the market capitalization attributable to Healthco is about ₹50,000 crore, as the net debt is small. Ebitda stands for earnings before interest, taxes, depreciation, and amortization.
Also Read: Tech Mahindra: What can upset its apple cart
Apollo Hospitals' market capitalization is now ₹1.08 trillion. So, the residual market capitalization of Apollo Hospitals, after deducting the valuation of Apollo Healthco is at ₹58,000 crore. With a net debt of around ₹5,000 crore, the implied EV/Ebitda valuation multiple of Apollo Hospitals comes to 20x based on Nomura's estimate of ₹3,150 crore Ebitda for FY26 (Apollo Health and Lifestyle having sugar clinic, dental clinic, etc. not considered due to its small size). Nomura's fair value multiple for Apollo Hospitals at 25x is higher than the derived implied multiple at 20x, implying room for upside.
The growth prospects of standalone Apollo Hospitals are strong. Its future growth is likely to be largely led by capacity additions, unlike the last three years to FY25, when it relied on average revenue per occupied bed (Arpob) for growth.
Apollo Hospitals had 8,025 operating beds at FY25 end. This is likely to rise by more than 50% as it plans to add nearly 4,400 beds over the next 3-4 years to address supply-side constraints, even though getting more patients is also crucial.
The management expects to maintain the Ebitda margin of the hospital business at 24% even after the large expansion.
Also Read: Nykaa's premium bet: A smart strategy if it delivers
The hospital business has a higher Ebitda margin but is more capital-intensive in nature, whereas the pharmacy business has a lower Ebitda margin but lower capital requirements. Besides, the separate listing of Apollo Healthco would mean that the shareholders of Apollo Hospitals would have an option to choose the business they want to remain invested in.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mint
3 hours ago
- Mint
IT's pay puzzle: Wipro, TechM median salaries drop despite rise in headcount
Median remuneration to employees at Wipro Ltd and Tech Mahindra Ltd fell simultaneously for the first time in eight years in FY25, despite both companies expanding their workforces. Analysts said that this indicates that the two IT service providers likely added more freshers as well as hired replacements at lower salaries to boost profitability. In FY25, Wipro and Tech Mahindra reported a decline of 0.6% and 6.52% in annual median salary, respectively, according to their annual reports. At Wipro, median salary totalled ₹9.78 lakh (around $11,000), whereas median salary at Tech Mahindra worked out to ₹18.3 lakh for males and ₹15.4 lakh for females. Median salary is the mid-point of a set of salaries arranged in ascending order, where half the salaries are higher and half lower. In contrast, the country's two largest IT outsourcers—Tata Consultancy Services Ltd and Infosys Ltd—increased their median salary to employees by 6.3% and 9.6%, respectively. Median salary at the country's third-largest software services provider HCL Technologies Ltd is not yet known as the company has yet to release its annual report for FY25. Wipro and Tech Mahindra—India's fourth and fifth-largest IT firms—last reported such a simultaneous decline in median salary in FY17. Individually, Pune-headquartered Tech Mahindra has seen its median remuneration decline six times in the past 10 years, whereas it is the third such instance for the Bengaluru-based Wipro. Median remuneration to employees at Wipro does not include whole-time directors. TCS and Infosys reported such a decline only once in the past decade, in FY21 and FY15, respectively. HCLTech is the only company among the country's top five software services firms to have never seen its median salary decline. Emails sent to Wipro and Tech Mahindra remained unanswered till press time. The fall in the median remuneration comes at a time when profitability of the country's largest IT outsourcers has been under pressure. These companies are exploring various ways to improve operating margins and one such way is to hire junior employees at lower costs. Lower median remuneration at Wipro and Tech Mahindra could imply that the companies added more freshers and/or hired candidates at lower salaries to replace talent at mid-management and senior levels, which led to a decline in median salaries, analysts said. 'Firms such as Wipro and TechM are following the lead of TCS by moving work to tier-4 locations and increasingly hiring from universities which are less prestigious. This is significantly lowering the cost of these employees and bringing down the average wages paid," said Peter Bendor-Samuel, founder of Everest Group, a Dallas-based tech research firm. He added that this was done to boost operating margins. 'The relentless focus on reducing cost is having its desired effect of allowing these firms to post higher margins," said Bendor-Samuel. TCS, Infosys and HCLTech reported operating margins of 24.3%, 21.1% and 18.3%, respectively, in FY25, respectively. TCS's margin declined by 30 basis points, while Infosys and HCLTech's margins grew by 40 basis points and 10 basis points, respectively. Wipro and Tech Mahindra improved their profitability the most last year. Wipro increased its operating margins by 100 basis points to 17.1%, whereas Tech Mahindra's profitability jumped 360 basis points to 9.7%. Hiring more employees can increase the median, or the mid-level salary. If a company adds headcount, the median salary is expected to increase because there are more employees in the company. Still, if the median salary goes down, it means that the number of employees earning salaries below the median amount has increased and that middle and senior-level employees have decreased. Both Wipro and Tech Mahindra added headcount last year by 732 and 3,276 employees, respectively. Wipro ended with 233,346 employees whereas Tech Mahindra ended with 148,731 employees. TCS added 6,433 employees to end with 607,979 people, whereas Infosys added headcount by 6,338 to 323,578 people. In contrast, HCLTech reduced staff by 4,061 to end with 223,420 people, becoming the only IT outsourcer of the top five to cut headcount last fiscal. A second analyst said churn at the top may also have contributed to the decline in median salaries at both Wipro and Tech Mahindra. 'The reduction in median remuneration to employees is a reflection of the fact that the companies may have hired more freshers and/or let go of lateral and senior staff," said a Mumbai-based analyst on the condition of anonymity. Both Wipro and Tech Mahindra have seen churn at the top. Mint reported on 26 June that Tech Mahindra saw at least 20 senior management movements at leadership levels, including service lines and geography heads, since March 2024. Even at Wipro, despite chief executive officer Srinivas Pallia's emphasis for promoting internal candidates to top roles, the company has seen significant leadership churn. Over the past two years, at least 30 senior executives at the level of senior vice-president and above have exited, driven either by better opportunities, or limited growth prospects under Pallia's predecessor Thierry Delaporte, who stepped down last year after four years at the helm. However, a third expert attributed the falling median salary to experienced employees accepting roles at lower salaries in a challenging job market. 'Because growth has been flat for these companies, they are refocusing on investing in their experienced staff while also lowering the overall wage bill. During this challenging market, there are also many experienced workers available, and it's easier to hire experienced talent at lower wage levels," said Phil Fersht, chief executive of HFS Research. He added that this trend is not a one-off and that IT outsourcers are looking at hiring employees at lower costs. 'There is a lot of flux in global services at the moment, with many providers laying off staff, which is making the talent pool of experienced people larger and bringing down wage demands," said Fersht. Wipro and Tech Mahindra were the only two companies in the top five Indian IT firms to see a second successive full-year revenue decline in FY25. Wipro and Tech Mahindra reported revenue declines of 2.72% and 0.21% to $10.5 billion and $6.3 billion, respectively, in FY25.
Mint
16 hours ago
- Mint
Apollo Hospitals: Simplifying corporate structure could lead to rerating
Apollo Hospitals Enterprise Ltd has decided to give its existing shareholders direct ownership of its subsidiary, Apollo Healthco Ltd. Apollo Healthco will have online, offline, retail, and wholesale pharmacy segments under one umbrella, apart from the digital consultation and treatment business of Apollo 24|7. The new entity will have nearly 667 million equity shares with a face value of ₹2 each. Apollo Hospitals' shareholders will receive 195.2 shares of Apollo Healthco for every 100 shares they hold. Apollo Healthco's listing is likely in 18-21 months. The exercise would mean that Apollo Hospitals would only have a 17.5% stake (direct plus indirect through its other subsidiaries) in Apollo Healthco, as against the earlier plan of having a 59.2% stake. Also Read: Will Torrent Pharma's big bet on JB Chemicals pay off? The two separate listed entities with dedicated leadership will allow the management teams to sharpen their focus on hospital and pharmacy businesses separately. Following the announcement, Apollo Hospitals shares touched a new 52-week high of ₹7,584.50 apiece on Tuesday. Growth potential Is there more steam left based on the separate valuation of the two businesses? Well, the answer depends on the management's ability to achieve the aspirational targets for its pharmacy business—Apollo Healthco. According to the company's presentation, Apollo Healthco's FY25 revenue (pro forma without the restructuring) was ₹16,377 crore. The management aspires for an operating revenue of ₹25,000 crore in FY27, which would mean a compound annual growth rate of 24% over the two years from FY25. This would require a significant pick-up in growth, given that the FY25 revenue had increased 19% year-on-year. Excluding Apollo 24|7 losses, the FY25 Ebitda margin was already about 6%. So, the Ebitda margin target of 7% in FY27 with operational efficiencies is achievable as it would only require Apollo 24|7 to achieve breakeven. If management is able to deliver on the aspirational numbers, it would mean an Ebitda of ₹1,750 crore in FY27. Based on the EV/ Ebitda multiple of 30x assigned by analysts at Nomura, the market capitalization attributable to Healthco is about ₹50,000 crore, as the net debt is small. Ebitda stands for earnings before interest, taxes, depreciation, and amortization. Also Read: Tech Mahindra: What can upset its apple cart Apollo Hospitals' market capitalization is now ₹1.08 trillion. So, the residual market capitalization of Apollo Hospitals, after deducting the valuation of Apollo Healthco is at ₹58,000 crore. With a net debt of around ₹5,000 crore, the implied EV/Ebitda valuation multiple of Apollo Hospitals comes to 20x based on Nomura's estimate of ₹3,150 crore Ebitda for FY26 (Apollo Health and Lifestyle having sugar clinic, dental clinic, etc. not considered due to its small size). Nomura's fair value multiple for Apollo Hospitals at 25x is higher than the derived implied multiple at 20x, implying room for upside. The growth prospects of standalone Apollo Hospitals are strong. Its future growth is likely to be largely led by capacity additions, unlike the last three years to FY25, when it relied on average revenue per occupied bed (Arpob) for growth. Apollo Hospitals had 8,025 operating beds at FY25 end. This is likely to rise by more than 50% as it plans to add nearly 4,400 beds over the next 3-4 years to address supply-side constraints, even though getting more patients is also crucial. The management expects to maintain the Ebitda margin of the hospital business at 24% even after the large expansion. Also Read: Nykaa's premium bet: A smart strategy if it delivers The hospital business has a higher Ebitda margin but is more capital-intensive in nature, whereas the pharmacy business has a lower Ebitda margin but lower capital requirements. Besides, the separate listing of Apollo Healthco would mean that the shareholders of Apollo Hospitals would have an option to choose the business they want to remain invested in.
Hindustan Times
21 hours ago
- Hindustan Times
Sensex and Nifty surge on optimism over US trade deal
Benchmark indices Sensex and Nifty rallied in early trade on Wednesday amid optimism around a possible trade agreement with the US. India's manufacturing sector growth rose to a 14-month high of 58.4 in June.(REUTERS file) Buying in IT blue-chip stocks also drove the equity markets higher during the initial trade. The 30-share BSE Sensex climbed 236.56 points to 83,933.85 in early trade. The 50-share NSE Nifty went up by 66.3 points to 25,608.10. From the Sensex firms, Infosys, Tech Mahindra, Tata Steel, Sun Pharma, Tata Consultancy Services and Tata Motors were among the biggest gainers. However, Bajaj Finserv, Asian Paints, Bharat Electronics and Bajaj Finance were among the laggards. India's manufacturing sector growth rose to a 14-month high of 58.4 in June marked by improved trends in output and new orders, alongside a record upturn in employment, a monthly survey said on Tuesday. The seasonally adjusted HSBC India Manufacturing Purchasing Managers' Index – an indicator of sector performance - was 57.6 in May. "The market is expected to open on a positive note, supported by strong domestic cues such as a 14-month high in manufacturing PMI, a narrowing trade deficit, and optimism around a potential trade agreement with the US," Vikas Jain, Head of Research at Reliance Securities, said in his pre-market views. Gross GST collection increased by 6.2 per cent to over ₹ 1.84 lakh crore in June but slipped below the ₹ 2 lakh crore mark recorded in the previous two months. The GST mop-up stood at ₹ 1.74 lakh crore a year ago, as per government data released on Tuesday. "After breaking the 24,500-25,000 range Nifty has moved to the new range of 25,200-25,800. Positive news about a possible trade deal between India and the US can help break the upper limit of the range but it would be difficult to sustain the Nifty at higher levels for long. A surprise element is the resilience of the US economy and corporate earnings, which in turn is imparting resilience to the US market, despite the tariffs," VK Vijayakumar, Chief Investment Strategist, Geojit Investments, said. In Asian markets, South Korea's Kospi, Japan's Nikkei 225 index and Shanghai's SSE Composite index were trading lower while Hong Kong's Hang Seng index quoted higher. The US markets ended on a mixed note on Tuesday. Global oil benchmark Brent crude traded 0.06 per cent up at USD 67.15 a barrel. Foreign Institutional Investors (FIIs) offloaded equities worth ₹ 1,970.14 crore on Tuesday, according to exchange data. In the previous trading session, the Sensex rose by 90.83 points or 0.11 per cent to settle at 83,697.29. The Nifty gained 24.75 points or 0.10 per cent to close at 25,541.80.
